INMUNOTEK listed in CEPYME500 of 2020


INMUNOTEK selected in CEPYME500 in the 2020 edition. This is an initiative of CEPYME (State Confederation of Small and Medium Enterprises) to identify, recognize and support the 500 leading companies in business growth in Spain. INMUNOTEK was already listed in 2017.

European Patent Granted


The European Patent Office has granted to INMUNOTEK the patent EP2982381B1. This refers to hypoallergenic neoglycoconjugates performed with non-oxidized mannan derived from S. cerevisiae to be used for the development of novel allergy vaccines targeting dendritic cells.

CIEGE Seal for INMUNOTEK at Business Excellence


INMUNOTEK obtains the CIEGE Seal for excellence in business management for the second consecutive year. This Seal certifies excellent management over 57 indicators from 10 categories: solvency, profitability, growth, employment, internationalization, corporate social responsibility, customer satisfaction, innovation, commercial risk management and digitization.

INMUNOTEK HELLAS new subsidiary

INMUNOTEK HELLAS is established in Athens, Greece, as a new European subsidiary of INMUNOTEK. With INMUNOTEK HELLAS, there are currently five subsidiaries of the INMUNOTEK Group around the world, and the second in Europe.

Top-ten PTO Inmunotek

INMUNOTEK Top-10 according to Pharma Tech Outlook

INMUNOTEK featured among the top-10 European immunotherapy providers by Pharma Tech Outlook, a specialized magazine in Pharma and Life Science technologies. The immunotherapy field covers different immune-based treatments for an increasing number of diseases. from allergies or cancer to autoimmune or infectious diseases.

INMUNOTEK at the A TU SALUD awards

INMUNOTEK is awarded for its research and innovative work in the field of Immunology in the IX Edition of the A TU SALUD Awards of the La Razón newspaper. The event was attended by the Mayor of Madrid, Mr. José Luis Martínez Almeida, who delivered the awards, and the Minister of Health of the Community of Madrid, Mr. Enrique Ruiz Escudero

Premio Nacional de Innovación_Inmunotek

INMUNOTEK receives the National Innovation Award

Their Majesties the Kings of Spain present INMUNOTEK with the National Innovation Award in the Small and Medium-Sized Entities (SME) category. The act presided over by the Kings took place at the Valencia Science Museum. It was attended by the Minister of Science and Innovation, Pedro Duque, local authorities. jury and guests. The National Innovation Award is the highest award given by the Government of Spain to recognize those entities that make innovation their main business growth strategy.


INMUNOTEK innovative entity granted by BLOCKPCT

INMUNOTEK obtains the certificate as innovative entity in the private and independent blockchain network of the Spanish Science and Technology Parks (BLOCKPCT) promoted by the Association of Science and Technology Parks of Spain (APTE).


Supply of Products and COVID-19

INMUNOTEK has implemented action measures to minimize the impact that the COVID-19 crisis is having due to the confinement situation established in Spain with the aim of guaranteeing the supply of its products to patients.



The MV130 project presented by INMUNOTEK has been selected by ITTN (International Technology Transfer Network) among more than 300 international projects for the first Roadshow sponsored by CAST (China Association for Science and Technology) in the fight against COVID-19. MV130 induces trained immunity and confers resistance to viral infections by activating innate immunity in a stable way through metabolic and epigenetic changes on innate immune cells.